WallStreetZenWallStreetZen

NASDAQ: CRSP
Crispr Therapeutics Ag Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CRSP

Based on 6 analysts offering 12 month price targets for Crispr Therapeutics Ag

Min Forecast
$56.00+4.77%
Avg Forecast
$82.67+54.66%
Max Forecast
$110.00+105.8%

Should I buy or sell CRSP stock?

Based on 6 analysts offering ratings for Crispr Therapeutics Ag.

Buy
Strong Buy
2 analysts 33.33%
Buy
3 analysts 50%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CRSP's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates CRSP as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their CRSP stock forecasts and price targets.

CRSP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-31
lockedlocked$00.00+00.00%2026-08-31
lockedlocked$00.00+00.00%2026-08-04Find Out Why
lockedlocked$00.00+00.00%2026-07-08
lockedlocked$00.00+00.00%2026-05-13
Piper Sandler
Bottom 2%
2
Strong BuyReiterates$110.00+105.80%2026-03-17

1 of 1

Forecast return on equity

Is CRSP forecast to generate an efficient return?

Company
29.92%
Industry
18.78%
Market
168.5%
CRSP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CRSP forecast to generate an efficient return on assets?

Company
19.71%
Industry
23.71%
CRSP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CRSP earnings per share forecast

What is CRSP's earnings per share in the next 3 years based on estimates from 22 analysts?

Avg 1 year Forecast
-$4.52
Avg 2 year Forecast
-$3.57
Avg 3 year Forecast
-$2.64

CRSP revenue forecast

What is CRSP's revenue in the next 3 years based on estimates from 23 analysts?

Avg 1 year Forecast
$30.2M+125.75%
Avg 2 year Forecast
$65.8M+391.19%
Avg 3 year Forecast
$147.8M+1,003.94%
CRSP's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRSP revenue growth forecast

How is CRSP forecast to perform vs Biotechnology companies and vs the US market?

Company
117.32%
Industry
33.02%
Market
13.51%
CRSP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRSP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRSP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRSP$53.45$82.67+54.66%Buy
DFTX$37.99$68.64+80.67%Strong Buy
ERAS$15.70$22.56+43.67%Strong Buy
PBLS$38.76$41.67+7.50%Strong Buy
ACAD$27.68$35.08+26.74%Buy
View Top Biotech Stocks

Crispr Therapeutics Ag Stock Forecast FAQ

Is Crispr Therapeutics Ag Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: CRSP) stock is to Buy CRSP stock.

Out of 6 analysts, 2 (33.33%) are recommending CRSP as a Strong Buy, 3 (50%) are recommending CRSP as a Buy, 1 (16.67%) are recommending CRSP as a Hold, 0 (0%) are recommending CRSP as a Sell, and 0 (0%) are recommending CRSP as a Strong Sell.

If you're new to stock investing, here's how to buy Crispr Therapeutics Ag stock.

What is CRSP's earnings growth forecast for 2026-2028?

(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.2%.

Crispr Therapeutics Ag's earnings in 2026 is -$451,139,000.On average, 22 Wall Street analysts forecast CRSP's earnings for 2026 to be -$437,050,792, with the lowest CRSP earnings forecast at -$553,391,392, and the highest CRSP earnings forecast at -$323,872,041. On average, 22 Wall Street analysts forecast CRSP's earnings for 2027 to be -$344,931,701, with the lowest CRSP earnings forecast at -$516,435,460, and the highest CRSP earnings forecast at -$51,778,916.

In 2028, CRSP is forecast to generate -$255,200,919 in earnings, with the lowest earnings forecast at -$595,085,264 and the highest earnings forecast at $696,477,180.

What is CRSP's revenue growth forecast for 2026-2028?

(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual revenue growth rate of 117.32% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.02%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.51%.

Crispr Therapeutics Ag's revenue in 2026 is $13,392,000.On average, 23 Wall Street analysts forecast CRSP's revenue for 2026 to be $2,923,308,978, with the lowest CRSP revenue forecast at $268,128,727, and the highest CRSP revenue forecast at $9,442,037,565. On average, 23 Wall Street analysts forecast CRSP's revenue for 2027 to be $6,360,442,714, with the lowest CRSP revenue forecast at $0, and the highest CRSP revenue forecast at $25,595,512,176.

In 2028, CRSP is forecast to generate $14,295,041,820 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $56,401,791,421.

What is CRSP's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CRSP) forecast ROA is 19.71%, which is lower than the forecast US Biotechnology industry average of 23.71%.

What is CRSP's Price Target?

According to 6 Wall Street analysts that have issued a 1 year CRSP price target, the average CRSP price target is $82.67, with the highest CRSP stock price forecast at $110.00 and the lowest CRSP stock price forecast at $56.00.

On average, Wall Street analysts predict that Crispr Therapeutics Ag's share price could reach $82.67 by Aug 31, 2027. The average Crispr Therapeutics Ag stock price prediction forecasts a potential upside of 54.66% from the current CRSP share price of $53.45.

What is CRSP's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CRSP) Crispr Therapeutics Ag's current Earnings Per Share (EPS) is -$4.74. On average, analysts forecast that CRSP's EPS will be -$4.52 for 2026, with the lowest EPS forecast at -$5.72, and the highest EPS forecast at -$3.35. On average, analysts forecast that CRSP's EPS will be -$3.57 for 2027, with the lowest EPS forecast at -$5.34, and the highest EPS forecast at -$0.54. In 2028, CRSP's EPS is forecast to hit -$2.64 (min: -$6.15, max: $7.20).

What is CRSP's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CRSP) forecast ROE is 29.92%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.